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Hepatitis C Virus Infection Upregulates CD55 Expression on the
Hepatocyte Surface and Promotes Association with Virus Particles
Budhaditya Mazumdar,a Hangeun Kim,a Keith Meyer,a Sandip K. Bose,a,b Adrian M. Di Bisceglie,a Ratna B. Ray,c Michael S. Diamond,d
John P. Atkinson,d Ranjit Raya,b
Departments of Internal Medicine,a Molecular Microbiology and Immunology,b and Pathology,c St. Louis University, and Department of Internal Medicine, Washington
University,d St. Louis, Missouri, USA
CD55 limits excessive complement activation on the host cell surface by accelerating the decay of C3 convertases. In this study,
we observed that hepatitis C virus (HCV) infection of hepatocytes or HCV core protein expression in transfected hepatocytes
upregulated CD55 expression at the mRNA and protein levels. Further analysis suggested that the HCV core protein or full-
length (FL) genome enhanced CD55 promoter activity in a luciferase-based assay, which was further augmented in the presence
of interleukin-6. Mutation of the CREB or SP-1 binding site on the CD55 promoter impaired HCV core protein-mediated up-
regulation of CD55. HCV-infected or core protein-transfected Huh7.5 cells displayed greater viability in the presence of CD81
and CD55 antibodies and complement. Biochemical analysis revealed that CD55 was associated with cell culture-grownHCV
after purification by sucrose density gradient ultracentrifugation. Consistent with this, a polyclonal antibody to CD55 captured
cell culture-grownHCV. Blocking antibodies against CD55 or virus envelope glycoproteins in the presence of normal human
serum as a source of complement inhibited HCV infection. The inhibition was enhanced in the presence of both the antibodies
and serum complement. Collectively, these results suggest that HCV induces and associates with a negative regulator of the com-
plement pathway, a likely mechanism for immune evasion.
The complement system performs a vital effector function inthe innate immune system by providing an efficient means for
targeting and eliminating infected cells and invadingmicroorgan-
isms, including free viral particles (1–3). Activation of the com-
plement cascade occurs primarily via the classical, alternative, or
lectin pathway (2, 4). These three pathways activate C3 via cleav-
age to C3a and C3b by the C3 convertases. C5 convertases are
generated by the association of C3b with the C3 convertases,
which in turn cleaves C5 into C5a and C5b. The release of C5b
initiates the nonenzymatic process of membrane-attack complex
(MAC) formation that then sequentially recruits C6, C7, C8, and
C9 proteins (1, 3, 5). TheMAC forms a pore-like structure within
the lipid envelope of the pathogen or the membrane of the in-
fected cells that ultimately leads to lysis. In order to avert damage
from excessive complement activation and MAC formation, host
cells express membrane-bound regulatory proteins to limit these
processes (6). Regulators of complement activation (RCA) are
expressed on the surfaces of host cells and include CD46, CD55,
and CD59 (7–9).
Hepatocytes are the primary sites for synthesis of complement
components in vivo. During an acute-phase (AP) response, the
biosynthesis of these components is increased by the action of AP
response-associated cytokines interleukin-1 (IL-1), IL-6, and tu-
mor necrosis factor alpha (TNF-) (10, 11). Hepatocytes may be
exposed to high local concentrations of complement components
under these conditions and could promote complement-medi-
ated damage (12–14). Decay-accelerating factor (DAF) or CD55 is
one of the key RCA proteins and is expressed on all serum-ex-
posed cells. CD55 limits excessive complement activation by in-
hibiting C3 convertase formation. It accelerates decay of C3 con-
vertases, which slows cleavage of C3.
Previous reports suggested that complement attack on anti-
body-sensitized hepatoma cells following a 3-day incubation with
a combination of AP cytokines resulted in an increased resistance
to complement-mediated lysis and decreased C3b deposition
(15). An increased hepatic synthesis of CD55 that could protect
hepatocytes from high local concentrations of complement gen-
erated during the AP response was observed (15). More recently,
primary human hepatocytes have been shown to be protected
from complement-mediated cell lysis by an enhanced synthesis of
complement-regulatory proteins, including CD55, induced by
proinflammatory cytokines like gamma interferon, IL-1, and
TNF- (16).
Recent studies have suggested that incorporation of the com-
plement-regulatory protein CD59 in HCV in plasma as well as
proteins derived from cell lines (17) protected HCV from anti-
body-dependent complement-mediated lysis. Analogously, HBV
Xprotein has been implicated in increasing expression of CD59 in
hepatoma cell lines. This resulted in a decrease in deposition of the
C5b-C9 complex on the hepatocyte cell surface, which contrib-
uted to resistance of the cells to complement-dependent lysis (18).
In this study, we have shown that HCV core protein enhanced
transcription and cell surface protein expression of CD55 in hepa-
tocytes. Moreover, CD55 was associated with purified HCV that
was grown in cells, and blocking antibodies against CD55 inhib-
ited infection of HCV in cell culture. Our results suggest that in-
duction of CD55 expression and its incorporation in HCV parti-
cles limit complement-mediated damage to infected cells and
released virus.
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Patientmaterials. Paired serum samples and liver biopsy specimens from
chronically HCV-infected patients (n 12) were used, as previously de-
scribed (19, 20). Commercially available control liver RNAwas purchased
(Clonetics, CA; CloneTech, CA; and Lonza, NJ) and used in this study.
Serum samples from healthy volunteers were used as controls. Serum
and/or liver samples were collected from subjects with their written con-
sent, and the human study protocol (protocol 10592) was approved by St.
Louis University internal review.
Cells and transfections. Immortalized human hepatocytes (IHH)
were generated and maintained as previously described (21, 22). IHH
were used for infection with HCV genotype 1a (clone H77) as previously
described (23). Huh7.5 cells were transfected using Lipofectamine 2000
(Life Technologies, Inc., MD) with plasmid DNA from a mammalian
expression vector (pcDNA3) containing the HCV genotype 1a full-length
(FL) genome or protein-specific genomic region under the control of a
cytomegalovirus (CMV) promoter. Stable colonies of transfectants were
selected using neomycin and pooled for subsequent studies to avoid po-
tential artifacts associated with clone-to-clone variation. Parental cells
transfected with empty vector DNA were used in parallel as a negative
control.
Flow cytometry. Parental HCV-infected andHCV genotype 2a (clone
JFH)-infected Huh7.5 cells were grown for 4 days, washed with phos-
phate-buffed saline (PBS), fixed with formaldehyde (final concentration,
2%), and incubated at 37°C for 10 min. Cells were centrifuged for 5 min
(200  g at 4°C) and washed with PBS containing 0.5% bovine serum
albumin (BSA) and 0.1% NaN3. Cells were sequentially incubated for 60
min with a 1:100 dilution of anti-CD55 antibody (clone BRIC216; EMD
Millipore, MA) in PBS containing 0.5% BSA and 0.1% NaN3. Cells were
washed, a fluorescein isothiocyanate-conjugated anti-mouse IgG anti-
body (Santa Cruz, CA) was added at a 1:400 dilution, and themixture was
incubated for 30 min. Washed cells were resuspended in 90% ice-cold
methanol for permeabilization, mixed gently, and placed at20°C for 10
min. Next, cells were centrifuged and washed twice in PBS containing
0.5% BSA and 0.1% NaN3. A mouse anti-core proteinmonoclonal anti-
body (MAb; clone C7-50; Thermo Scientific) was added at a 1:100 dilu-
tion, and the cells were incubated for 60min.Washed cells were incubated
with an Alexa 647-conjugated rabbit anti-mouse IgG (Santa Cruz) at
1:400 dilutions for 30 min. Finally, cells were washed, resuspended in 500
l cold PBS, and subjected to flow cytometric analysis (Becton, Dickin-
son) using software for processing data (Cell Quest software; BD Immu-
nocytometry Systems).
Luciferase reporter assay. The human CD55 promoter region was
generated from genomic DNA of Huh7.5 cells. The CD55 promoter re-
gion was amplified by PCR from known sequences (24) using restriction
site-containing synthetic oligonucleotide primers and cloned into a
PGL3-Luc vector cassette as previously described (19). Huh7.5 cells were
transfected with the CD55 promoter-driven luciferase reporter construct
(200 ng/well) alone or together with HCV core or nonstructural proteins
(NS2, NS3/4A, or NS5A) or a full-length infectious cDNA (HCV-FL)
construct (500 ng/well) in a 24-well plate. In experiments assessing the
effects of IL-1 and/or IL-6, cells were treated with the cytokine (10 ng/ml
for IL-1 and 50 ng/ml for IL-6) at 24 h posttransfection. Cells were
solubilized with reporter lysis buffer (Promega,WI) at 48 h after transfec-
tion, and the clarified lysateswere subjected to the luciferase reporter assay
using a luminometer (Opticomp II; MGM Instruments, CT).
Quantitative real-time PCR. CD55 mRNA quantitation was per-
formed by real-time PCR analysis using specific TaqMan primers and
probes (Applied Biosystems assay identification [ID], Hs00892618_m1),
after normalizing with 18S rRNA (Hs03928992-g1). RNA was isolated
with the TRIzol reagent (Life Technologies) from liver biopsy specimens,
HCV-infected Huh7.5 cells, or Huh7.5 cells transiently transfected with
plasmids expressing specific HCV genomic regions. cDNA synthesis was
performed using random hexamers and a SuperScript III first-strand syn-
thesis kit (Invitrogen), and the levels of CD55 mRNA were evaluated.
Generation of site-specific mutations in CD55 promoter element.
Three separate mutations in the transcription factor binding sites of the
CD55 promoter were generated. Briefly, the original pGL3-CD55-Luc
plasmid construct was used tomutate the binding sites of three transcrip-
tion factors (CREB, SP-1, and AP-1) in the CD55 promoter using a
QuikChange II-E site-directed mutagenesis kit (Agilent Technologies)
following the manufacturer’s instructions. The primers used (5=-3=; with





CCTTGGTGACGTGGAGCCCCAGCCC), and AP-1-(reverse) (GGGCT
GGGGCTCCACGTCACCAAGGGT).
Cloned mutated DNAs with luciferase tags were used in the promoter
assay.
Western blotting. Proteins in cell lysates were resolved by 10% SDS-
PAGE under reducing conditions, transferred onto a nitrocellulosemem-
brane, and blotted with the appropriate primary antibody. Signal was
detected using a peroxidase-conjugated secondary antibody (Bio-Rad,
CA). Protein bands were visualized using an enhanced chemilumines-
cence detection kit (Super SignalWest Pico; ThermoChemical Company,
IL). Cellular actin was detected for comparison of the protein load in each
lane. The difference in intensities of the bands was obtained by densitom-
etry scanning of Western blots and ImageJ software analyses.
Complement-mediated cytolysis assay. Huh7.5 cells mock treated,
infected with HCV genotype 2a, or constitutively expressing HCV core
proteinweremaintained for 3 days. Cells were treatedwith serial dilutions
of CD81 monoclonal antibody (isotype IgG2b; stock concentration, 200
g/ml; Santa Cruz, CA) with or without human serum (5% dilution) as a
source of complement (Quidel) in the presence or absence of function-
blocking CD55 monoclonal antibody (isotype IgG1; clone BRIC216;
EMDMillipore, MA).
Alternatively,Huh7.5 cells constitutively expressingHCVcore protein
were infected with vesicular stomatitis virus (VSV; Indiana) at a multi-
plicity of infection of 0.5. Cells were incubated for 16 h at 37°C before
addition of serial dilutions of VSV G glycoprotein (VSV-G)-specific as-
cites (ATCC) and a 5% dilution of human serum as a source of comple-
ment (Quidel) in the presence or absence of function-blocking CD55
monoclonal antibody, as mentioned above. VSV-infected cells treated
either with human serum alone or with VSV-specific antisera acted as
negative controls. Cells were incubated for 4 h at 37°C before measure-
ment of cell viability using a CellTiter 96 AQueous One cell viability assay
(Promega Corporation, WI).
Density gradient-purified HCV preparation. Cell culture-adapted
HCV of genotype 2a (JFH1) was grown to an infectious titer1,000-fold
higher than that of the parent virus inHuh7.5 cells (25). Sucrose gradient-
purified cell culture-grown virus was kindly provided to us byGeorge Luo
(University of Alabama at Birmingham). Biochemical analysis of gradi-
ent-purified HCV suggested the presence of viral proteins. Adenovirus
was grown in 293 cells and purified by CsCl density gradient centrifuga-
tion as previously described (26). Gradient-purified virus preparations
were estimated for protein content using a NanoOrange protein quanti-
tation kit (Invitrogen, OR) following the supplier’s procedure.
Suppression of HCV infection by CD55-specific antibody and hu-
man serumcomplement.Cell culture-grownHCVgenotype 1a or 2a (23)
was used at a set virus number (100 focus-forming units [FFU]) for
infection in Huh7.5 cells. Briefly, virus was incubated at 37°C in the pres-
ence or absence of CD55 antibody for 1 h. Cells were incubated with the
virus-antibody mixture at 37°C for 5 h, rinsed, and incubated in medium
for 96 h. Cells were rinsed with PBS and fixed with methanol for 20 min,
followed by 0.2% Triton X-100 in PBS for 5 min. Cells were blocked with
3% BSA–PBS, followed by an overnight incubation at 4°C with an anti-
body specific to HCV NS5A protein (9E10; kindly provided by Charlie
Rice, Rockefeller University, New York, NY). Secondary antibody (anti-
Complement Regulation by HCV
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mouse Alexa 488) was incubated over cells for 1 h at room temperature,
andDAPI (4=,6-diamidino-2-phenylindole) was used for nuclear staining
and contrast imaging. Infected cells were visualized under a Leica micro-
scope, and fields were selected at random.
To quantify antibody- and/or complement-dependent suppression of
HCV infection, real-time PCR was performed (27, 28). A predetermined
number of FFU of cell culture-grown HCV was incubated with HCV
envelope glycoprotein vaccine serum (1:100) in the presence or absence of
a function-blocking mouse monoclonal antibody (1:50) to CD55. Un-
treated HCV and virus treated only with CD55 antibody were used as
controls. After antibody addition, virus was incubated for 30min at 37°C,
followed by an additional 30 min of incubation in the presence of a nor-
mal human serum pool (1:20) as a source of complement. Virus-contain-
ing supernatants were incubated with Huh7.5 cells for 5 h at 37°C. Cells
were rinsed twice and incubated at 37°C for 96 h. Cells were rinsed and
lysed, and RNA was isolated using an RNeasy minikit (Qiagen). cDNA
was generated using a SuperScript III kit (Invitrogen), followed by quan-
titative real-time PCR to measure levels of viral RNA (28). A standard
curve generated from virus dilutions of known titer was used as a com-
parative control, and 18S rRNA was used as an internal control.
Biotinylation of human Ig to HCV E1/E2. Sera (samples 19, 20, 21,
and 34) that were from individuals vaccinated with the HCV envelope
glycoproteins and that reacted against three E2-derived linear epitopes
and one E1 epitope by enzyme-linked immunosorbent assay (ELISA) (29)
were used to prepare Ig using protein A/G chromatography cartridges
(Pierce). Antibodies to E1/E2 glycoproteins were biotinylated using an
EZ-link sulfo-NHS biotinylation kit (Thermo Scientific, Rockford, IL)
following the manufacturer’s protocol.
HCV-capture ELISA using anti-CD55 antibody. Rabbit anti-CD55
(Santa Cruz, CA) or a control rabbit antibody to an internal cellular pro-
tein, caspase 8 (BD Pharmingen), was coated on an ELISA plate (Corning
Costar flat-bottom high-binding EIA/RIA 3690 plate) in PBS (pH 7.4; 0.4
g/well) at 37°C for 2 h. The plate was blocked with 2% BSA in PBS. Cell
culture-grown stock HCV genotype 1a or 2a (culture supernatant) of
known titer (international units and numbers of FFU/ml) was added in
triplicate to experimental or control wells. After incubation at 4°C over-
night, wells were washed and bound virus or virus envelope glycoproteins
were detected by serial addition of a biotin-labeled pooled anti-HCV en-
velope glycoprotein-specific human serum sample generated in a vaccine
development study (29), avidin-horseradish peroxidase (HRP) conjugate
(Pierce Immunopure streptavidin-HRP conjugate), and peroxidase sub-
strate (Pierce Chemicals, IL). The absorbance at 450 nm was read and
presented after subtraction of reagent-control values reacting against
BSA-coated negative controls (0.25).
Statistical analysis. Results were expressed as the mean 	 standard
deviation (SD) from four independent experiments, and statistical anal-
yses were performed using a two-tailed unpaired Student t test or one-way
analysis of variance (ANOVA) in GraphPad Prism, version 5, software
(GraphPad, La Jolla, CA). A P value of0.05 was considered statistically
significant.
RESULTS
HCV infection enhancesCD55 expression.CD55mRNAexpres-
sion in HCV-infected liver biopsy specimens in a cohort of pa-
tients studied previously (19, 20) was evaluated by real-time PCR
analysis. CD55 expression was enhanced (3- to 4-fold) (P 
0.0001) in all 12 HCV-infected liver biopsy specimens compared
with that in three healthy liver RNA samples (Fig. 1). The changes
inCD55 level did not correlate with the stage of liver fibrosis or the
results of laboratory tests (tests for rheumatoid factor, serum al-
bumin, or alkaline phosphatase levels) in paired blood specimens
from the same limited cohort of patients, indicating that liver
fibrosis does not modulate CD55. The purpose of using the same
cohort from previous studies for this analysis was to be able to
work on a broad range of distinct butmechanistically linked com-
plement components in the same cohort of chronically HCV-in-
fected patients.
CD55 expression increases upon HCV infection of hepato-
cytes. We also compared CD55 mRNA expression levels in IHH
infected with HCV genotype 1a and primary human hepatocytes
(PHH) infected with cell culture-grown HCV genotype 2a with
those in the corresponding uninfected parental cells by quantita-
tive reverse transcription-PCR (qRT-PCR). An 2.5-fold or
greater induction in CD55 mRNA was observed in IHH infected
with HCV genotype 1a or PHH than in parental hepatocytes (Fig.
2A). We also observed a 6.3-fold increase in CD55 expression in
HCVgenotype 2a-infectedHuh7.5 cell lysates compared to that in
the mock-infected control by Western blotting using densitome-
try scanning analysis (Fig. 2B). The induction of CD55 expression
in HCV-infected hepatocytes was reflected at the cell surface in
both HCV genotype 1a-infected IHH (Fig. 2C) and HCV geno-
type 2a-infected Huh7.5 cells (data not shown), as determined by
flow cytometry.
CD55 expression is increased in the presence of HCV core
protein. Sincewe identified a transcription-regulatory role of core
proteinwith a pleiotropic effect onmultiple cellular genes (30), we
investigated the role ofHCVcore protein onCD55mRNAexpres-
sion. Huh7.5 cells transfected with the HCV core protein gene
exhibited an 5-fold increase (P  0.001) in CD55 mRNA ex-
pression compared to empty vector-transfected cells (Fig. 3A).
Similarly, we observed an 6-fold enhancement (P  0.001) of
CD55 transcript levels in cells transfected with an infectious HCV
full-length cDNA. In contrast, transfection of HCV NS3/4A or
NS5A failed to change CD55 levels compared to those in the vec-
tor control. We also observed 4.8-fold higher levels of CD55 pro-
tein expression in Huh7.5 cells stably expressing HCV core pro-
tein than in the mock-transfected control by Western blotting
using densitometry scanning analysis (Fig. 3B). Flow cytometry
analysis corroborated the increased cell surface expression of
CD55 on Huh7.5 cells transfected with core protein (Fig. 3C).
However, a similar treatment of IHH (Fig. 3D) resulted in no
FIG 1 HCV infection upregulates CD55 mRNA expression. Upregulation of
CD55 mRNA expression in HCV genotype 1a-infected paired liver biopsy
specimens (marked with 3-digit numbers) compared with the expression of
CD55 mRNA in non-HCV-infected control liver tissues (C1, C2, and C3) was
determined by qRT-PCR. Results were normalized to those for 18S rRNA and
shown as individual samples organized according to the stage of fibrosis of the
patient liver (P  0.0001, as a group of experimental samples compared to
controls using one-way ANOVA).
Mazumdar et al.
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enhancement of CD55 expression by flow cytometry analysis,
likely due to the presence of already enhanced CD55 levels in IHH
due to immortalization by HCV core protein. Thus, upregulation
of CD55 expression in HCV-infected hepatocytes may occur due
to a transcriptional regulatory role of the virus core protein.
CD55 promoter activity is enhanced by HCV core protein.
Our observation of enhanced CD55 mRNA levels in HCV infec-
tion prompted us to investigate whether this is caused by an up-
regulation in CD55 promoter activity resulting in an enhanced
transcription rate. We used a CD55 promoter construct with a
luciferase reporter gene tag and transfected it into Huh7.5 cells
alongwith plasmids encoding individualHCVproteins (core pro-
tein, NS3/4A, or NS5A) as well as the full-length infectious HCV
cDNA. Cells were lysed 48 h after transfection, and promoter ac-
tivity was measured by luciferase assay. Our results suggested that
CD55 promoter activity was enhanced in the presence of HCV
polyprotein (Fig. 4A). Among the HCV proteins, this effect was
apparent only in the presence of core protein, with an 8-fold
enhancement in CD55 promoter activity (Fig. 4A). In compari-
son, CD55 promoter activity was unaffected inHCVNS3/4A- and
NS5A-transfected cells.
The expression of CD55 in hepatoma cells is reportedly regu-
lated by IL-1/IL-6 cytokines as well as TNF- (15). We next
examined the effect of these cytokines on CD55 promoter activity
inHuh7.5 cells.We observedmaximal levels of CD55 induction in
the presence of IL-6 (4-fold) followed by IL-1 (2.7-fold)
(Fig. 4B). TNF- did not affect CD55 promoter activity either
alone or when combined with IL-1 and IL-6. Previous reports
had indicated that HCV core protein induces IL-6 expression in
IHH (31), which can potentially act in an autocrine manner to
stimulate CD55 expression. As such, we determined the impact of
IL-1 and IL-6 onCD55promoter activity in the presence ofHCV
core protein. While IL-1 caused negligible enhancement of
CD55 promoter activity in core protein-transfected hepatocytes,
addition of IL-6 resulted in an 2.2-fold induction of promoter
activity (Fig. 4C).
Next, we investigated the mechanism of HCV core protein-
mediated upregulation of CD55 expression. We generated lucif-
erase-tagged CD55 promoter constructs containing loss-of-func-
tion point mutations in the binding sites of the transcription
factors CREB, AP-1, and SP-1 (32). We observed a reduction in
HCV core protein-mediated induction of CD55 promoter activity
if the promoter encoded point mutations in CREB or SP-1 bind-
ing sites; this indicates that interaction of these transcription fac-
tors with their cognate binding sites is important for HCV core
protein-mediated upregulation of CD55 (Fig. 4D). However, a
mutation affecting the AP-1 binding site did not influence HCV
core protein-mediated CD55 upregulation. Thus, our results sug-
gest that induction of CD55 promoter activity by HCV core pro-
tein is mediated by CREB and SP-1 transcription factors.
Cells infected with HCV or expressing core protein inhibit
antibody-dependent, complement-mediated cytolysis.Previous
reports indicated that enhanced CD55 expression in association
with the acute-phase response protects hepatoma cells from com-
plement-mediated cell damage (15). Here, we examined whether
enhanced CD55 expression in hepatoma cells infected with HCV
can inhibit complement-mediated cytolysis and thereby promote
cell survival. Initially, HCV genotype 2a-infectedHuh7.5 cells and
uninfected control cells were treated with CD81-specific antibody
in the presence or absence of a function-inhibiting CD55-neutral-
izing antibody (BRIC216). Antibody to CD81 was observed to
induce a weak level of cell killing in control Huh7.5 cells upon the
addition of complement. Incubation of CD81 antibody-treated
cells revealed a consistent increase in cell viability inHCV-infected
cells (35% inhibition of total cell death) compared to uninfected
control cells (Fig. 5A). The addition of antibody to CD55 further
decreased cell viability in HCV-infected cells, approaching levels
similar to those apparent in control cells. In contrast, the addition
of antibody to CD55 on control cells exhibited a negligible de-
crease in cell viability, suggesting that enhanced CD55 availability
on theHuh7.5 cell surface is related to enhanced survival of HCV-
infected cells. Experiments using HCV core protein-expressing
stable transfectants in the place of HCV infection of Huh7.5 cells
exhibited similar results (Fig. 5B).
As HCV envelope glycoproteins do not assemble at the cell
surface for budding, we usedVSV as an efficient and sensitive viral
model system for inhibition of complement-mediated lysis. Here,
the enhanced availability of VSV G glycoprotein on the infected
cell surface compared to that of cellular CD81 protein is believed
to be able to convey a stronger indication of cell viability in re-
sponse to HCV core protein-mediated CD55 overexpression in a
complement-mediated cell lysis assay. For this experiment,
FIG 2 CD55 expression increases upon HCV infection of hepatocytes. (A)
Enhanced CD55 mRNA expression in IHH infected with HCV genotype 1a
and PHH infected with HCV genotype 2a detected by qRT-PCR. Parental
hepatocytes were used as a control for comparison. CD55mRNAexpression in
parental hepatocytes was arbitrarily set at 1, and the results for the infected
hepatocytes were statistically significantly different (P  0.0001) using one-
way ANOVA. (B)Detection ofHCV core protein expression inHCV genotype
2a-infected Huh7.5 cells by Western blotting. Cellular actin expression was
used as a loading control in each lane. (C) Staining with anti-CD55 antibody
from HCV genotype 1a-infected IHH is shown by flow cytometry analysis.
Complement Regulation by HCV
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Huh7.5 cells ectopically expressing HCV core protein were in-
fectedwithVSV and treatedwith aVSV-G-specific antibody in the
presence or absence of a CD55 antibody. As described above, an
additional incubation with pooled human serum as a source of
complement was used to trigger antibody-dependent comple-
ment-mediated cytolysis. The presence of HCV core protein in-
duced cell viability that was significantly greater than the viability
of vector-transfected control cells when cell deathwas triggered by
antibody-dependent (anti-VSV) complement-mediated cytolysis
afterVSV infection (Fig. 5C). Similar to the experiments described
above, 50% of all complement-mediated cell killing in this ex-
perimental system was inhibited by the presence of HCV core
protein expression (80% cell killing versus 40% for HCV core
protein-expressing cells). Also, the degree of cell viability con-
ferred by HCV core protein expression was reduced upon addi-
tion of a neutralizing anti-CD55 antibody, suggesting that CD55
induction by HCV core protein is necessary for evasion of com-
plement-mediated cell death in virus-infected cells. Together, our
results suggested that the presence ofHCVcore protein alone or in
HCV-infected cells confers protection via increased CD55 expres-
sion that would be beneficial to virus survival.
CD55 associates withHCVproduced in cell culture.Cell cul-
ture-adapted HCV of genotype 2a (JFH1) grows to an infectious
titer 1,000-fold greater than that of its parent virus (33). We
used sucrose gradient-purified cell culture-adapted HCV geno-
type 2a to examine the CD55 association with the virus particles.
We also used a CsCl gradient-purified unrelated adenovirus as a
negative control in this experiment. The clonedHCV core protein
genomic region was transfected into Huh7.5 cells and used for
analysis of CD55 protein expression by Western blotting. The
presence of a CD55-specific band was detected in sucrose density
gradient-purified cell culture-grown HCV genotype 2a but was
absent from purified adenovirus even after loading a 15-fold ex-
cess (Fig. 6A). These results suggested thatCD55 associateswith or
is incorporated into HCV.
In separate experiments, we examined for a direct association
of CD55 with intact or disintegrated HCV envelope components
using a capture ELISA. Infectious HCV from cell culture medium
was captured with a rabbit anti-CD55 or a negative-control rabbit
antiserum to an internal cellular protein (caspase 8), and then
binding was detected with an antibody preparation from HCV
envelope glycoprotein-vaccinated subjects. The results revealed
that anti-CD55 antibody could efficiently capture both HCV ge-
notype 1a and HCV genotype 2a from cell culture-grown stock
virus (Fig. 6B), and an increased optical density correlated with a
higher virus titer. To further verify the localization of CD55 on the
HCV surface, we used a rabbit polyclonal antibody to CD55
(amino acids 35 to 353) for inhibition of a predetermined 100
fluorescent focus-forming units of virus. Use of anti-CD55 anti-
body (2g/ml) inhibited50%fluorescent focus formation from
HCV of both genotypes compared to that from untreated control
virus (Fig. 6C). Together these results indicated that CD55 asso-
ciates with the HCV surface and virus infectivity can be prevented
by CD55-specific antibody.
FIG 3 Enhancement of CD55 expression in hepatocytes is mediated by HCV core protein. (A) Upregulation of CD55 mRNA expression in Huh7.5 cells
transfected with HCV core protein or FL polyprotein compared with the level of expression in untreated control cells detected by real-time PCR. NS3/4A and
NS5Adid not affect CD55 expression. CD55mRNAexpression in untreated controls was arbitrarily set at 1, and the results were statistically significantly different
(P 0.0001) using one-way ANOVA. The experiments were done in triplicate and repeated three times. (B) Western blot analysis of lysates from Huh7.5 cells
stably transfected with HCV core protein reveals upregulation of CD55. (C and D) Cell surface expression of membrane-bound CD55 on HCV core protein-
transfected or vector-transfected Huh7.5 cells and IHH, as detected by flow cytometry.
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To observe the effect of CD55 incorporation on virus fitness,
we incubated HCV with a function-blocking CD55 monoclonal
antibody (BRIC216; Millipore) alone or in the presence of a pre-
viously identified nonneutralizing concentration (1%) of heat-
inactivated human serum from a recent HCV vaccine trial (29).
Subsequently, pooled human serum from healthy volunteers was
added at levels (10%) previously observed to have no negative
effects upon virus fitness and further incubated at 37°C for 30min
prior to incubation with naive Huh7.5 cells. Incubation of HCV
genotype 2a with antibody to CD55 in the presence of comple-
ment prior to addition on Huh7.5 cells modestly inhibited (2-
fold) HCV infection, as suggested from the viral RNA level within
cells by qRT-PCR (Fig. 6D). A similar effect was also observed
using HCV anti-E1/E2 human serum alone in the presence of
complement (29). Addition of both antisera to E1/E2 and func-
tion-blocking CD55 resulted in an enhanced reduction (
5-fold)
of HCV infectivity in Huh7.5 cells due to increased virus lysis
under CD55-inhibiting conditions. These results further sug-
gested that CD55 is physically associated with the HCV surface
and may act to inhibit the innate immune function in HCV-in-
fected individuals.
FIG4 HCVcore protein enhances CD55 promoter activity regulated by IL-1
and/or IL-6. (A) Enhancement of CD55 promoter activity by HCV core pro-
tein and FL polyprotein in a luciferase reporter assay. NS3/4A and NS5A did
not display a major effect on CD55 promoter activity. The results obtained
were statistically significantly different (P 0.0001 for vector versus core pro-
tein and P  0.0003 for vector versus FL polyprotein; the results for NS3/4A
and NS5A were not significant with respect to the results for the vector) from
the values for the vector control by the unpaired two-tailed t test. (B)Cytokine-
mediated induction of CD55 promoter activity. IL-1, IL-6, and TNF- were
used individually or in combination. Results obtained were statistically signif-
icantly different (P  0.0001) from those for the uninduced control using
one-way ANOVA. (C) IL-1- and IL-6-mediated induction of CD55 mRNA
expression in the presence of HCV core protein. Results obtained were statis-
tically significantly different (P 0.0001) from those for the uninduced con-
trol using one-way ANOVA. (D) Reduction in HCV core protein-mediated
induction of luciferase expression from a CD55 promoter engineered with
point mutations in transcription factor binding sites. The upregulation of
CD55 promoter activity in Huh7.5 cells transfected with HCV core protein
compared to the level of regulation in the vector control determined by a
luciferase reporter assay is shown. A reduction in the levels of core protein-
mediated induction was observed in the CD55 promoter harboring point mu-
tations of both CREB as well as SP-1 binding sites, whereas an alteration in the
AP-1 binding site did not affect core protein-mediated induction of CD55
promoter activity.
FIG 5 Inhibition of antibody-dependent complement-mediated cell death by
HCV. (A andB)Huh7.5 cells were infectedwithHCVgenotype 2a or leftmock
infected. Alternatively, Huh7.5 cells were stably transfected with theHCV core
protein gene or vector. Cells were treated with anti-CD81MAb (isotype 2a) at
the indicated reciprocal dilutions and complement (Quidel) at a 1:5 dilution.
The experiments were done in triplicate, were repeated three times, and gave
consistent results. The difference in cell viability between control and HCV-
infected cells (*, P  0.0083 to 0.001) compared to that for core protein-
expressing cells was statistically significant (**, P  0.0557 to 0.238). (C)
Huh7.5 cells, with or without constitutive expression of HCV core protein,
were infected with VSV, followed by treatment with anti-VSV-G antibody and
pooled human serum as a source of complement proteins with or without
CD55-neutralizing antibody. Cell viability was measured by the CellTiter 96
AQueous One cell viability assay (Promega). The experiments were done in
triplicate, were repeated three times, and gave consistent results. The differ-
ence in cell viability between control and HCV core protein-expressing cells
was statistically significant (***, P 0.0128 to P 0.0001).
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In this study, we observed an enhancement of CD55 expression at
themRNAandprotein levels in hepatoma cells infectedwithHCV
or ectopically expressing the core protein. Correspondingly,
CD55 mRNA expression was also elevated in liver biopsy speci-
mens from a small cohort of patients with chronic HCV infection.
It is quite difficult to prepare cells for evaluation of multiple pa-
rameters (mRNA expression for quantitative real-time PCR and
protein expression for flow cytometry or immunohistochemistry)
with material from a single needle biopsy specimen from an indi-
vidual patient. Our rationale for using human clinical materials
was to provide a more physiological linkage to our cell culture
studies, as a facile and tractable small-animal model for HCV in-
fection is currently lacking. HCV core protein is amultifunctional
regulator of gene expression and assumes different roles during
the course of infection (30). Our results suggest that expression of
HCVcore protein augments CD55 promoter activity in aCREBor
SP-1 transcription factor-dependent manner. The promoter and
related transcription factors forCD55 expression in some cell lines
have been identified (32). The CD55 promoter has different tran-
scription factor binding sites for CREB, AP-1, and SP-1. In our
study with Huh7.5 cells, we utilized the known information from
the literature and mutated binding sites of the previously identi-
fied transcription factors. At this point, we cannot rule out the
possibility that additional transcription factors and their cognate
binding sites exist in the Huh7.5 CD55 promoter. We observed
that point mutations at known CREB or SP-1 binding sites inhib-
ited HCV core protein-mediated activation of the CD55 pro-
moter. Double mutations in the already identified binding sites
are likely to cause greater inhibition of CD55 promoter activity by
HCV core protein. A detailed mechanism of HCV-mediated
CD55 promoter regulation in Huh7.5 cells would require a more
in-depth analysis. HCV appeared to upregulate CD55 on target
cells to prevent complement-mediated opsonization or lysis, with
a benefit of protecting the infected cells themselves from comple-
ment attack.We also detected the presence of CD55 in association
with highly purified HCV through biochemical and immunolog-
ical analysis.
A functional analysis for the outcome of enhanced CD55 ex-
pression was performed. HCV-infected or core protein-express-
ing hepatoma cells were treated with an antibody to cell surface
tetraspanin protein CD81 in the presence or absence of a CD55-
neutralizing antibody. Antibody-treated cells were exposed to hu-
man serum as a source of complement. An increase in cell viability
FIG 6 Association of CD55 proteins with HCV. (A) Sucrose density gradient-purified HCV was tested by Western blotting for detection of CD55. Gradient-
purified adenovirus type 5 (Ad5) was used as a negative control. The amount of protein estimated from gradient-purified adenovirus type 5 was 15-fold higher
than the amount of purified HCV loaded in Western blot analysis. (B) Cell culture-grown HCV was captured by antibody to CD55 coated on an ELISA plate.
Captured HCV E1/E2 was detected by envelope glycoprotein-specific avidin-conjugated human antibodies. The results from 4 independent experiments are
presentedwith standard errors. (C) Inhibition of cell culture-grownHCVgenotype 1a or 2a infectivity byCD55-specific rabbit antiserum. (D) qRT-PCR analysis
for inhibition of HCV genotype 2a infectivity in Huh7.5 cells by a function-blocking murine MAb (IgG1) to CD55, a suboptimal dilution of HCV-neutralizing
anti-E1/E2 human serum (1/100), or both in the presence of pooled normal human serum (NHS) as a source of complement. Results from three independent
experiments using samples in triplicate are presented. The difference in viral infectivity between the control and antibody treatments was statistically significant
(*, P 0.0139; **, P 0.0003; ***, P 0.0001).
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was apparent in HCV-infected cells and HCV core protein-ex-
pressing cells compared to the viability of untreated negative-
control cells. HCV core protein expression in hepatocytes also
inhibited antibody-dependent complement-mediated cytolysis
triggered byVSV infection as amodel system.However,HCVcore
protein-mediated viability was reduced in the presence of block-
ing antibodies to CD55, further highlighting its role in the inhibi-
tion of complement-mediated lysis. We found CD55 to be associ-
ated with density gradient-purified cell culture-propagated HCV.
In support of this, function-blocking antibody to CD55 or human
anti-E1/E2modestly neutralizedHCV infectivity, and antibody to
E1/E2 in the presence of anti-CD55 enhancedHCVneutralization
in the presence of normal human serum as a source of comple-
ment.
Establishment of chronicHCV infection inmost patients high-
lights that this virus is able to effectively evade innate and adaptive
immune responses, including complement. We have reported
previously that HCV core and NS5A proteins can transcription-
ally repress induction of the complement components C3 and C4
by reducing expression of key transcription factors (19, 20). Com-
plement-regulatory proteins CD46, CD55, and CD59 limit exces-
sive complement-mediated damage to host cells. Each regulator
attenuates complement activation at different stages in the enzy-
matic cascade.WhereasCD46 is a cofactor protein for the cleavage
of C3b to iC3b (34), CD55 accelerates the decay of the C3 conver-
tases (reviewed in reference 35). CD59, in contrast, attenuates
MAC formation (36). ncreased expression of a complement reg-
ulator(s) on the surface of host cells is associated with significant
protection against complement-mediated lysis (8, 37–39). Viruses
inhibit complement activation through a panoply ofmechanisms.
For instance, the genomes of herpesviruses and poxviruses encode
homologs of complement regulators (40). As a different strategy,
human immunodeficiency virus, cytomegalovirus, herpes sim-
plex virus, Ebola virus, vaccinia virus, and influenza virus all es-
cape antibody-dependent complement-mediated lysis by incor-
porating (hijacking) host RCA proteins onto the surface of the
virion (reviewed in reference 17). They often produce comple-
ment binding proteins that attach the host’s inhibitor to their
membrane. Incorporation of CD55 into lentiviral particles ren-
dered themmore resistant to complement-mediated inactivation
(41, 42). Analogously, parainfluenza virus type 5 (PIV5) and
mumps virus (MuV) incorporate CD46 into progeny virions to
gain partial resistance to neutralization by normal human serum.
Complement regulators are often species specific, and their rela-
tive contribution to viral evasion from complement attack may
vary. Future studies are planned to determine how the relative
level of RCAupregulation inHCV-infected cells or the stoichiom-
etry of incorporation into the virion modulates virus infectivity.
Upregulation of CD55 and CD59 expression serves to protect
hepatocytes from high local concentrations of complement gen-
erated during the acute-phase response (15). This enhancement of
CD55 is induced by acute-phase cytokines in an HCV-indepen-
dent mechanism. A reduction in complement-mediated tumor
lysis by higher CD55 levels could facilitate tumorigenesis and con-
tribute to the pathogenesis of hepatocellular carcinoma that is
observed during chronic HCV infection. Indeed, in both breast
and colorectal cancer patients, expression of CD55 in tumors has
been associated with a poor prognosis (43, 44). Also, earlier re-
ports indicated that expression of CD46, another complement-
regulatory protein, was significantly enhanced in HCC, appar-
ently in an effort to escape from tumor-specific complement-
mediated cytotoxicity (45). It will be interesting to investigate in
detail the relationship between HCV infection, CD55 expression,
and induction of HCC as a follow-up of the current study.
HCV incorporates CD59 into the viral lipid bilayer at biologi-
cally functional levels (17) and protects against antibody-depen-
dent complement-mediated lysis. Thus, it is difficult to examine
the role of CD55 in maintaining cell viability related to comple-
ment attack by depleting it alone in cells supporting HCV growth.
A recent report (46) demonstrated that, among the three comple-
ment-regulatory proteins, HCV associates with CD59. To test if
infected cells are putative sources for the acquisition of CD59 by
HCV-Jc1, the authors analyzed Huh7.5 cells by flow cytometry.
CD46 andCD59were expressed efficiently and comparably on the
cell surface, whereas less CD55 was detected. Expression of CD59
in Huh7.5 cells infected with HCV-Jc1, however, was not up- or
downregulated, indicating that viral replication or proteins did
not affect CD59 expression. Why CD55 was not detected in these
virions remains uncertain, although it could be due to differences
in the reactivity of antibodies or purification strategies.
In summary, upregulation of CD55 expression on HCV-in-
fected hepatocytes can lead to increased resistance of the cells to
cytokine-stimulated complement activation and subsequent
complement-dependent lysis. This would enable HCV to evade
complement attack and multiply to higher titers within infected
cells. The CD55 association with intact HCV particles potentially
renders them resistant to antibody-dependent or -independent
complement-mediated lysis. Future in vivo studies will be de-
signed to elucidate the contribution of RCAs to viral fitness during
HCV infection and the survival of unrelated pathogens in HCV-
infected individuals.
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